It is possible to consider applying CA19-9, CA125, NLR, PLR, BDNF and their CV to the screening of patients with inter medium-risk ovarian cancer in the future, which may guide the monitoring of ovarian cancer recurrence and guide patients to timely referral to gynecological oncologists for comprehensive evaluate. This evidence concerns the gene BDNF and ovarian carcinoma.